News for Silo Pharma Inc. (SILO)

Silo Pharma (SILO) has successfully concluded dosing in a crucial safety and toxicology study for its main product, SPC-15. This study was requested by the U.S.

Silo Pharma (SILO) completes dosing in FDA-requested safety and toxicology study for PTSD drug SPC-15. Results from the 7-day study expected within 60 d

SARASOTA, FL, July 16, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ('Silo” or the 'Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced completion of dosing in a U.S. Food and Drug Administration (FDA)-requested 7-day safety and toxicology large animal study of its lead asset SPC-15, and bioanalytical and safety/toxicology results for such study are expected within 60 days.

Planned submission of IND application in 2025; Phase 1 clinical trial to follow if IND application approved No new PTSD drug approvals in the U.S. in nearly 25

Silo Pharma (SILO) advances SPC-15, a PTSD drug candidate, towards an IND submission planned for 2025. Preclinical study data for SPC-15 expected in the

**media[646914]**

SiloPharma, under the ticker SILO, has secured a service agreement with Resyca BV, a medical technology firm, to explore the application of a novel microchip-ba

**media[633056]**

**media[628749]**

SARASOTA, FL, May 15, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. ( SILO) (”œSilo” or the ”œCompany”), a developmental stage biopharmaceutical company fo

SiloPharma, with ticker SILO, has announced a public offering involving 3,333,338 shares of common stock. Accompanying these shares are series A-1 and A-2 warra

Silo Pharma (SILO) announces a $2 million public offering priced at $0.60 per share. The offering includes 3,333,338 shares and Series A-1 and A-2 warra

Silo Pharma (SILO) has initiated a collaboration with Frontage Laboratories to conduct a 7-day safety and toxicology study on its primary asset, SPC-15, as requ

Silo Pharma (SILO) advances PTSD drug SPC-15 with key safety study. IND submission targeted for 2025, with Phase 1 clinical trials pending approval. SPC-15

Clear Regulatory Path to Clinical Trials for Intranasal PTSD Therapy Targeting Multi-Billion-Dollar Market SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Si

**media[625638]**

Silo Pharma (SILO) reported encouraging outcomes from its preclinical trial focused on SP-26, an innovative extended-release ketamine implant. The study indicat

SP-26 ketamine implant by Silo Pharma (SILO) met all preclinical study endpoints. Sustained drug release of up to 22 days achieved post-implantation.

**media[610232]**